Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Queensland Health
Express Scripts
Healthtrust
Julphar
Dow
Boehringer Ingelheim
Daiichi Sankyo
Chinese Patent Office

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,470,853

« Back to Dashboard

Which drugs does patent 8,470,853 protect, and when does it expire?

Patent 8,470,853 protects ZECUITY and is included in one NDA.

This patent has twenty patent family members in twelve countries.
Summary for Patent: 8,470,853
Title:Transdermal methods and systems for the delivery of anti-migraine compounds
Abstract: Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.
Inventor(s): Anderson; Carter R. (Inver Grove Heights, MN), Morris; Russell L. (Lindstrom, MN), Sebree; Terri B. (Gladwyne, PA)
Assignee: NuPathe Inc. (Conshohocken, PA)
Application Number:13/105,585
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 8,470,853

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Teva Branded Pharm ZECUITY sumatriptan succinate SYSTEM;IONTOPHORESIS 202278-001 Jan 17, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,470,853

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,973,058 Transdermal methods and systems for the delivery of anti-migraine compounds ➤ Sign Up
9,272,137 Transdermal methods and systems for the delivery of anti-migraine compounds ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Baxter
Queensland Health
Mallinckrodt
AstraZeneca
US Department of Justice
Citi
Fuji
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.